Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Rijken

Showing results (61-70 of 101) with videos related to

Pageof 11
Sort By:
Thrombosis and Haemostasis|November 19, 1997
Inhibition of mannose receptor-mediated clearance of tissue-type plasminogen activator (t-PA) by dextran: a new explanation for its antithrombotic effectF Noorman, M M Barrett-Bergshoeff, M Bekkers, et al.
European Journal of Clinical Investigation|December 1, 1985
Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitorA D'Angelo, C Kluft, J H Verheijen, et al.
The Biochemical Journal|March 15, 1993
Role of the glycosaminoglycan component of thrombomodulin in its acceleration of the inactivation of single-chain urokinase-type plasminogen activator by thrombinG A de Munk, J F Parkinson, E Groeneveld, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 9, 2001
Polylysine as a vehicle for extracellular matrix-targeted local drug delivery, providing high accumulation and long-term retention within the vascular wallD V Sakharov, A F Jie, M E Bekkers, et al.
Journal of Thrombosis and Haemostasis : JTH|June 11, 2005
The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptorN Bovenschen, D C Rijken, L M Havekes, et al.
Thrombosis Research|June 15, 1986
Characterization and fibrin-binding properties of different molecular forms of pro-urokinase from a monkey kidney cell cultureG Wijngaards, D C Rijken, A L van Wezel, et al.
Thrombosis and Haemostasis|January 23, 1992
The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibilityB J Potter van Loon, D C Rijken, E J Brommer, et al.
Thrombosis and Haemostasis|August 1, 1995
Native and non-glycosylated recombinant single-chain urokinase-type plasminogen activator are recognized by different receptor systems on rat parenchymal liver cellsM E van der Kaaden, D C Rijken, E Groeneveld, et al.
Journal of Thrombosis and Haemostasis : JTH|April 22, 2004
Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresisA H C Guimarães, M M Barrett-Bergshoeff, A Gils, et al.
Arzneimittel-Forschung|March 1, 1988
Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteersE Seifried, P Tanswell, D C Rijken, et al.
Pageof 11

Showing results (61-70 of 101) with videos related to

Sort By:
Pageof 11
Thrombosis and Haemostasis|November 19, 1997
Inhibition of mannose receptor-mediated clearance of tissue-type plasminogen activator (t-PA) by dextran: a new explanation for its antithrombotic effectF Noorman, M M Barrett-Bergshoeff, M Bekkers, et al.
European Journal of Clinical Investigation|December 1, 1985
Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitorA D'Angelo, C Kluft, J H Verheijen, et al.
The Biochemical Journal|March 15, 1993
Role of the glycosaminoglycan component of thrombomodulin in its acceleration of the inactivation of single-chain urokinase-type plasminogen activator by thrombinG A de Munk, J F Parkinson, E Groeneveld, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 9, 2001
Polylysine as a vehicle for extracellular matrix-targeted local drug delivery, providing high accumulation and long-term retention within the vascular wallD V Sakharov, A F Jie, M E Bekkers, et al.
Journal of Thrombosis and Haemostasis : JTH|June 11, 2005
The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptorN Bovenschen, D C Rijken, L M Havekes, et al.
Thrombosis Research|June 15, 1986
Characterization and fibrin-binding properties of different molecular forms of pro-urokinase from a monkey kidney cell cultureG Wijngaards, D C Rijken, A L van Wezel, et al.
Thrombosis and Haemostasis|January 23, 1992
The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibilityB J Potter van Loon, D C Rijken, E J Brommer, et al.
Thrombosis and Haemostasis|August 1, 1995
Native and non-glycosylated recombinant single-chain urokinase-type plasminogen activator are recognized by different receptor systems on rat parenchymal liver cellsM E van der Kaaden, D C Rijken, E Groeneveld, et al.
Journal of Thrombosis and Haemostasis : JTH|April 22, 2004
Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresisA H C Guimarães, M M Barrett-Bergshoeff, A Gils, et al.
Arzneimittel-Forschung|March 1, 1988
Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteersE Seifried, P Tanswell, D C Rijken, et al.
Pageof 11